NanoVibronix announced agreements to raise up to $50 million through the sale of Series H convertible preferred stock to an institutional investor. The initial closings, expected by July 21, 2025, include nearly $8.9 million from 8,889 shares and $2.2 million from 2,222 shares, with an option to purchase up to $44 million more within 36 months.
The preferred stock converts into common shares at $1.01 per share. NanoVibronix plans to use $5 million from the proceeds to redeem certain outstanding Series X preferred stock.
CEO Dr. Doron Besser highlighted the financing will accelerate growth, expand market reach, and support investment in high-potential products. The Tyler, Texas–based company develops UroShield, a portable ultrasonic therapy device using patented low-frequency surface acoustic wave technology, with a next-gen robotic system currently in development.
Follow MEDWIRE.AI for updates on innovative therapeutic technologies.
